Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Corcept Therapeutics Inc.

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Adamas Pharmaceuticals, Inc.

Charleston Laboratories, Inc. is involved in developing treatments for acute pain and associated symptoms such as opioid-induced nausea and vomiting. Self-described as focusing on innovative therapeutics.

Charleston Laboratories, Inc.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Horizon Therapeutics Public Limited Company

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated

Corcept Therapeutics focuses on cortisol modulation in pursuit of novel treatments for severe disorders, including endocrinology, oncology, metabolism, and neurology. This is self-described.

Metric
Company Name	Corcept Therapeutics Inc.	Adamas Pharmaceuticals, Inc.	Charleston Laboratories, Inc.	Horizon Therapeutics Public Limited Company
Symbol	CORT	ADMS		HZNP
MSH ID	COM:CORCEPT	COM:ADAMASPHARMA	COM:CHARLESTONLABS	COM:HORIZONTHERAPEUTICS
Market	STOCKS	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Drug Manufacturers - Specialty & Generic	Pharmaceuticals	Drug Manufacturers - General
Country	US	US	US	IE
Stage
Employee Count	352	138		2.19K
Website	corcept.com	adamaspharma.com	charlestonlabs.com	horizontherapeutics.com
LinkedIn
Founders

Metric
Market Cap	6.03B
Enterprise Value
Monthly Web Traffic	53.48K
Web Traffic Growth	3.98
Valuation
Raised Capital

Metric
Revenue	482.38M	3.63B
Revenue (LTM)
Revenue (NTM)
Gross Profit	475.89M	2.71B
EBITDA	109.64M	1.11B
Operating Income	107.28M	617.41M
Net Income	106.14M	521.48M
EPS	1.02	2.28
Diluted EPS	0.94	2.22
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.99	0.75
Operating Profit Margin	0.23	0.14
EBITDA Margin	0.23	0.31
Net Profit Margin	0.23	0.12
Return on Equity	0.24	0.09
Return on Assets	0.18	0.05
Return on Capital Employed	0.22	0.06

COM:CORCEPT

Corcept Therapeutics

Last Close

55.92

22/11 21:00

Market Cap

3.19B

Beta: -

Volume Today

648.55K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	24.15	60.74
P/B Ratio	4.78	5.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.13	9.79
EV Multiple	41.21	38.99

Metric
Days Sales Outstanding	39.44	71.85
Days Payables Outstanding	1.00K	34.56
Days Inventory Outstanding	435.27	92.88
Operating Cycle	476.98	189.19
Cash Conversion Cycle	-212.43	142.54
Asset Turnover	0.80	0.39

Metric
Operating Cash Flow	127.04M	1.26B
Free Cash Flow	126.90M	1.13B
Cash Flow to Debt	1.64K	0.41
Operating Cash Flow/Sales	0.26	0.29
Free Cash Flow Yield	0.07	0.03

Metric
Cash & Equivalents	135.55M	2.35B
Accounts Receivable	-10.07M	-43.46M
Inventory	7.73M	169.56M
Goodwill		1.01B
Debt to Capitalization	0.01	0.33
Debt to Assets	0.00	0.28
Current Ratio	3.54	4.27
Quick Ratio	5.48	3.50

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.10	0.06
R&D to Revenue	0.37	0.14
SG&A to Revenue		0.21